Sun Pharmaceutical Industries, India’s largest drugmaker by market capitalisation and revenue, is reportedly evaluating the acquisition of US-based Organon, a company focused on women’s health with a rapidly expanding presence in the biosimilars market. The deliberations are at an early stage and are based on inputs from people familiar with the matter.
A decade after Ranbaxy, another landmark move
Importantly, the potential transaction comes nearly ten years after Sun Pharma’s landmark acquisition of Ranbaxy Laboratories. If completed, the Organon deal would emerge as the most ambitious takeover undertaken by Sun’s billionaire founder, Dilip Shanghvi, widely regarded as one of India’s most astute pharmaceutical dealmakers. The move signals a renewed appetite for large-scale, transformative acquisitions.
$10 billion deal could redefine industry records
The proposed acquisition is expected to carry an enterprise value of around $10 billion, including debt. This would make it the largest cross-border acquisition ever by an Indian pharmaceutical company. Describing the deal as “transformative,” the report noted that it could significantly strengthen Sun Pharma’s position in the US market, the world’s largest and most competitive pharmaceutical arena.
Building on recent US-focused investments
Notably, Sun Pharma has already demonstrated its intent to deepen its US presence. In 2023, the company acquired Concert Pharmaceuticals for $576 million, securing the rights to deuruxolitinib (Leqselvi), a branded therapy for alopecia areata. That acquisition marked a strategic shift toward differentiated and specialty products in regulated markets.
A decisive step in reshaping Sun’s global footprint
As reported by firstpost.com, taken together, a successful Organon acquisition would represent far more than Sun Pharma’s biggest deal to date. Instead, it would serve as a decisive statement of intent—underscoring the company’s ambition to reshape its global footprint, strengthen its US portfolio, and play a larger role in high-growth segments such as biosimilars and women’s health.
